Back to Browse Journals » Drug Design, Development and Therapy » Volume 2

Development and targeted use of nilotinib in chronic myeloid leukemia

Authors Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour

Published 10 November 2008 Volume 2008:2 Pages 233—243


Review by Single-blind

Peer reviewer comments 3

Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Abstract: The development of imatinib has resulted in sustained hematologic and cytogenetic remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired resistance has been traced to Bcr-Abl kinase domain mutations. Several strategies have been developed to overcome the problem of imatinib resistance, including imatinib dose escalation, novel targeted agents and combination treatments. A second generation of tyrosine kinase inhibitors was developed, which displays increased potency towards Bcr-Abl and is able to target the majority of CML mutant clones. Nilotinib (Tasigna®, AMN107, Novartis) is a close analog of imatinib with approximately 20-fold higher potency for BCR-ABL kinase inhibition. Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in CML post imatinib failure, with a good tolerance. Nilotinib has been approved for CML patients in chronic and accelerated phases, post imatinib failure.

Keywords: nilotinib, imatinib-resistance, imatinib-intolerance, CML

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review

Elias Jabbour, Jorge Cortes, Hagop Kantarjian

Core Evidence 2009, 4:207-213

Published Date: 5 October 2009

Readers of this article also read:

Relaxin inhibits cardiac fibrosis and endothelial–mesenchymal transition via the Notch pathway

Zhou X, Chen X, Cai JJ, Chen LZ, Gong YS, Wang LX, Gao Z, Zhang HQ, Huang WJ, Zhou H

Drug Design, Development and Therapy 2015, 9:4599-4611

Published Date: 11 August 2015

High-throughput sequencing of 16S rDNA amplicons characterizes bacterial composition in cerebrospinal fluid samples from patients with purulent meningitis

Liu A, Wang C, Liang Z, Zhou ZW, Wang L, Ma Q, Wang G, Zhou SF, Wang Z

Drug Design, Development and Therapy 2015, 9:4417-4429

Published Date: 7 August 2015

Evaluation of calcified carotid atheroma on panoramic radiographs and Doppler ultrasonography in an older population

Atalay Y, Asutay F, Agacayak KS, Koparal M, Adali F, Gulsun B

Clinical Interventions in Aging 2015, 10:1121-1129

Published Date: 8 July 2015

Effects of strontium ranelate on bone formation in the mid-palatal suture after rapid maxillary expansion

Zhao SY, Wang XX, Li N, Chen Y, Su YR, Zhang J

Drug Design, Development and Therapy 2015, 9:2725-2734

Published Date: 21 May 2015

The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo

Wang C, Wang X, Zhong T, Zhao Y, Zhang WQ, Ren W, Huang D, Zhang S, Guo Y, Yao X, Tang YQ, Zhang X, Zhang Q

International Journal of Nanomedicine 2015, 10:2229-2248

Published Date: 19 March 2015

Folate-modified lipid–polymer hybrid nanoparticles for targeted paclitaxel delivery

Zhang L, Zhu D, Dong X, Sun H, Song C, Wang C, Kong D

International Journal of Nanomedicine 2015, 10:2101-2114

Published Date: 16 March 2015

Life-threatening asthma attack during prolonged fingolimod treatment: case report

Zecca C, Caporro M, Györik S, Gobbi C

Patient Preference and Adherence 2014, 8:987-989

Published Date: 14 July 2014

Solubilization of beclomethasone dipropionate in sterically stabilized phospholipid nanomicelles (SSMs): physicochemical and in vitro evaluations

Sahib MN, Abdulameer SA, Darwis Y, Peh KK, Tan YT

Drug Design, Development and Therapy 2012, 6:29-42

Published Date: 17 February 2012

Central corneal thickness in black Cameroonian ocular hypertensive and glaucomatous subjects

Christelle Domngang Noche, André Omgbwa Eballe, Assumpta Lucienne Bella

Clinical Ophthalmology 2010, 4:1371-1377

Published Date: 24 November 2010